Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus vaccine recombinant bivalent - Shanghai Zerun Biotechnology

Next Previous
Search
Drug Profile

Human papillomavirus vaccine recombinant bivalent - Shanghai Zerun Biotechnology

Alternative Names: Cervical cancer vaccine - Shanghai Zerun Biotechnology; HPV-16/18 vaccine - Shanghai Zerun Biotechnology; HPV-2 vaccine - Shanghai Zerun Biotechnology; Human papillomavirus (types 16, 18) L1 virus-like particle vaccine - Shanghai Zerun Biotechnology; Recombinant human papillomavirus bivalent (types 16 and 18) vaccine - Shanghai Zerun Biotechnology; VACETA; Wozehui®

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Zerun Biotechnology Co; Walvax Biotechnology
  • Developer Shanghai Zerun Biotechnology Co
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Human papillomavirus infections

Most Recent Events

  • 18 Feb 2025 Registered for Human papillomavirus infections (Prevention) in Indonesia (Unspecified route)
  • 27 Sep 2022 Launched for Human papillomavirus infections (In adolescents, In children, Prevention, In adults) in China (IM) (Shanghai Zerun Biotechnology pipeline, September 2022)
  • 27 Sep 2022 Registered for Human papillomavirus infections (In adolescents, In children, Prevention, In adults) in China (IM) (Shanghai Zerun Biotechnology pipeline, September 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top